一分钟看懂
这是一项关于淋巴瘤的III 期研究，登记的药物或干预包括Obinutuzumab；Glofitamab；Rituxumab；Tocilizumab；Gemcitabine；Oxaliplatin，当前状态为研究进行中，已停止招募。登记地点显示中国北京、广州、哈尔滨、上海等城市有研究中心记录。是否仍有名额以及是否值得进一步询问，需要向研究中心确认。
药物或干预
Obinutuzumab；Glofitamab；Rituxumab；Tocilizumab；Gemcitabine；Oxaliplatin · III 期
登记条件中文摘要
年龄范围：18岁及以上
登记的基本范围为不限性别，年龄18岁及以上；以下仅摘录8项专业入选条件，需结合英文原文并由研究团队确认。
登记记录列出8项主要排除条件，具体医学含义需结合英文原文并由研究团队确认。
中国哪些地方有记录
以下地点来自登记信息，不代表此刻仍有名额；请向研究中心确认最新情况。
- Peking University Third Hospital · 北京
- Sun Yet-sen University Cancer Center · 广州
- Harbin Medical University Cancer Hospital · 哈尔滨
- Fudan University Shanghai Cancer Center · 上海
- Tianjin Cancer Hospital · 天津
- Wuhan Union Hospital Tongji Medical College, Huazhong University of Science and Technology · 武汉
- Zhejiang Cancer Hospital · 浙江省
- Henan Cancer Hospital · 郑州
入选条件原文摘录
以下为摘录，请打开原始登记查看完整入排标准。
- * Histologically confirmed diffuse large B-cell lymphoma (DLBCL), not otherwise specified
- * Relapsed/refractory (R/R) disease, defined as follows: Relapsed = disease that has recurred ≥6 months after completion of the last line of therapy; Refractory = disease that either progressed during the last line of therapy or progressed within 6 months (\<6 months) of the last line of prior therapy
- * At least one (≥1) line of prior systemic therapy
- * Participants who have failed only one prior line of therapy must not be a candidate for high-dose chemotherapy followed by autologous stem cell transplant, as defined by the study protocol
- * Confirmed availability of tumor tissue, unless unobtainable per investigator assessment. Freshly collected biopsy is preferred. Archival tissue is acceptable
- * At least one bi-dimensionally measurable (≥1.5 cm) nodal lesion, or one bi-dimensionally measurable (≥1 cm) extranodal lesion, as measured on computed tomography (CT) scan
- * Eastern Cooperative Oncology Group (ECOG) Performance Status of 0, 1, or 2
- * Adequate hematologic function (unless attributable to the underlying disease, as established by extensive bone marrow involvement or associated with hypersplenism secondary to the involvement of the spleen by DLBCL per the investigator), as defined by the study protocol
联系前需要确认
请继续确认中心是否启动、疾病分型、既往治疗、检查费用和知情同意安排。
查看登记信息
登记号：NCT04408638；登记信息更新于 2026-10-02；本站同步于 2026-10-08。